{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:08:01Z","timestamp":1786122481007,"version":"build-2736575974"},"reference-count":9,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk & Safety in Medicine"],"published-print":{"date-parts":[[2026,8]]},"abstract":"\n Background<\/jats:title>\n Flurbiprofen (FLU) is a phenylalkanoic acid derivative which is one of the most commonly used nonsteroidal anti-inflammatory drug (NSAID).<\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n A 27-year-old woman with no known previous diseases presented with chest pain, rhinorrhoea, dry cough, increased lacrimation and symptoms of laryngeal irritation (throat clearing, hoarseness, mild sore throat). She was taking FLU 100\u00a0mg tablet (tb) orally, and these complaints began 30\u00a0min following drug ingestion. The cardiopulmonary examination and electrocardiogram (ECG) were normal.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We determined that a potentially fatal and very rare combination of allergic reactions from FLU use in association with symptom of laryngeal irritation, acute diffuse pharyngitis and increased lacrimation were possibly responsible for her symptoms.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These symptoms terminated by intravenous (IV) Pheniramine maleate and Prednisolone within 2\u00a0hours of their onset. The patient was recommended to refrain from using FLU permanently.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/09246479251411123","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:21:41Z","timestamp":1766575301000},"page":"481-482","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Flurbiprofen-induced upper respiratory and ocular adverse effects in a patient having non-cardiac chest pain"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-8271","authenticated-orcid":false,"given":"Erkan","family":"Gencer","sequence":"first","affiliation":[{"name":"Mehmet Akif \u0130nan Education and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106847"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12073"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.04.030"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2011.587580"},{"key":"e_1_3_4_6_2","volume-title":"Medical Genetics Summaries [Internet]","author":"Dean L","year":"2012","unstructured":"Dean L. Flurbiprofen therapy and CYP2C9 genotype. 2019 Feb 11. In: Pratt VM, Scott SA, Pirmohamed M, et al. (eds). Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US), 2012."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.15"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200405000-00002"},{"key":"e_1_3_4_9_2","unstructured":"Agency for Healthcare Research and Quality. Comparative Effectiveness Review Number 38. Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. Executive summary. March 16 2012."},{"key":"e_1_3_4_10_2","volume-title":"Flurbiprofen information from Drugs.com","author":"Drugs.com [Internet]","year":"2016","unstructured":"Drugs.com [Internet]. Flurbiprofen information from Drugs.com, 2016. [Truven Health Analytics Updated July 1st, 2016]. Available from: https:\/\/www.drugs.com\/cons\/flurbiprofen.html"}],"container-title":["International Journal of Risk & Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251411123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479251411123","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251411123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:20:45Z","timestamp":1786098045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479251411123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/09246479251411123"],"URL":"https:\/\/doi.org\/10.1177\/09246479251411123","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/09246479251411123\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251411123\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251411123\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251411123\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251411123\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251411123\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251411123\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}